Pharmbiotest
Private Company
Funding information not available
Overview
Pharmbiotest Poland is a Polish CRO with over a decade of experience, providing end-to-end clinical and bioanalytical services with a focus on bioequivalence studies for generic and hybrid medicines. The company leverages its GLP/GCP-certified clinical facility and bioanalytical laboratory to deliver integrated, cost-effective solutions for drug development partners. Its core value proposition is a full-package service model that reduces client logistics costs while ensuring regulatory compliance and data quality. Recent activities include expanding its US collaborations and conference presence.
Technology Platform
Integrated GLP/GCP-certified clinical and bioanalytical service infrastructure, featuring a clinical facility and a lab with 7+ mass spectrometry systems and over 30 validated bioanalytical methods.
Opportunities
Risk Factors
Competitive Landscape
Pharmbiotest competes in the crowded CRO market, facing large global firms (e.g., IQVIA, Parexel) and other regional European CROs. Its differentiation lies in its integrated, full-package service for bioequivalence studies, its EU regulatory base, and a focus on cost efficiency. Competition is based on quality, price, regulatory expertise, and geographic reach.